Jin Rong Jie·2025-07-29 03:16Group 1 - The core viewpoint of the articles highlights the strong performance of the Hong Kong stock market, particularly in the innovative pharmaceutical sector, with significant gains in related stocks and ETFs [1][2] - The Hong Kong Innovation Drug 50 ETF (513780) has seen a remarkable increase of 100% year-to-date, indicating robust investor interest and confidence in the sector [1] - WuXi AppTec reported a substantial revenue of 20.64% growth year-on-year, reaching 20.799 billion yuan, and a net profit increase of 101.92%, amounting to 8.561 billion yuan, marking a significant milestone of over 10 billion yuan in quarterly revenue for the first time [1] Group 2 - The top ten constituents of the CSI Hong Kong Stock Connect Innovative Drug Index account for 69.65% of the index, including high-quality A-share companies like Innovent Biologics and Stone Pharmaceutical [2] - The innovative drug sector in China is at a new historical starting point, with domestic companies enhancing their competitiveness and expanding overseas, supported by favorable policies [2] - The industry is experiencing rapid revenue growth and is transitioning into a new profit-driven cycle, presenting investment opportunities in high-quality, undervalued companies within the sector [1][2]